On January 4, 2022 PRISM BioLab, a Japan based biotechnology company with a proprietary peptide mimetic small molecule drug discovery platform, reported it has entered into a multi-target research collaboration and licensing agreement with Roche and Genentech, a member of the Roche Group (Press release, PRISM Pharma, JAN 4, 2022, View Source [SID1234598134]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, PRISM BioLab will provide its proprietary library of peptide mimetic small molecules, the PepMetics Library, for screening against targets selected by Roche and Genentech. Upon identification of hit compounds, Roche and Genentech may elect to further develop and commercialize the compounds.

PRISM BioLab is eligible to receive an upfront payment, success-based milestone payments and royalties on future net sales. Specific financial terms are not disclosed.